Toolkit helps explain valproate risks in pregnancy

Healthcare professionals have been urged to use a patient toolkit to explain the risks of taking valproate medication during pregnancy.

Earlier this year the Medicines and Healthcare products Regulatory Agency (MHRA) issued an information pack on valproate, which is prescribed to patients with epilepsy and bipolar disorders.

When taken during pregnancy, the medication can increase the risk of birth defects and developmental disorders.

Risk in pregnancy

The valproate patient guide sets out the risks of taking the medication when pregnant, and explains what patients taking it should do if they are planning a pregnancy.

MHRA’s vigilance and risk management of medicines division deputy director Sarah Branch told last month’s Royal College of Psychiatrists international congress the toolkit was intended to support healthcare professionals.

Further information:

Valproate patient guide